<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-156824" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Latent Tuberculosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Price</surname>
            <given-names>Cody</given-names>
          </name>
          <aff>University of Queensland, Australia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nguyen</surname>
            <given-names>Andrew D.</given-names>
          </name>
          <aff>University of Queensland, University of Western Australia</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Cody Price declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Nguyen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-156824.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p><italic toggle="yes">Mycobacterium tuberculosis</italic>&#x000a0;is a significant human pathogen. This bacterium primarily causes pulmonary disease but can spread to involve any organ and manifest as acute, chronic, or latent infection.<xref ref-type="bibr" rid="article-156824.r1">[1]</xref>&#x000a0;Tuberculosis is a global disease, but the disease burden disproportionately&#x000a0;impacts low-income countries&#x000a0;and vulnerable populations, including those who are homeless or unsheltered, incarcerated, or who use intravenous drugs.<xref ref-type="bibr" rid="article-156824.r2">[2]</xref>&#x000a0;The financial burden of tubercular illness and treatment can consume livelihoods among these populations.<xref ref-type="bibr" rid="article-156824.r3">[3]</xref></p>
        <p>In high-income countries with a low prevalence of tuberculosis, public health interventions focus on detecting and treating patients with latent tuberculosis (TB) infection.<xref ref-type="bibr" rid="article-156824.r4">[4]</xref>&#x000a0;Latent TB infection may reactivate to cause active and infectious TB disease that can spread throughout the population. Identification and characterization of individuals with latent TB infection and at risk of reactivation is imperative for public health but requires balancing the benefits of therapy with potential harms.&#x000a0;</p>
        <p>For a comprehensive discussion of the epidemiology, etiology, pathophysiology, histopathology, evaluation, and management of tuberculosis, please see StatPearls' companion topic, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/30653">"Tuberculosis."</ext-link></p>
      </sec>
      <sec id="article-156824.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>The bacterium&#x000a0;<italic toggle="yes">Mycobacterium tuberculosis</italic>&#x000a0;is the causative agent of TB disease. The genus&#x000a0;<italic toggle="yes">Mycobacterium&#x000a0;</italic>contains&#x000a0;many nontuberculous mycobacteria (NTM), but all mycobacteria are bacilli with a cell envelope containing high levels of mycolic acids.<xref ref-type="bibr" rid="article-156824.r5">[5]</xref>&#x000a0;The unique cell envelope of mycobacteria is impervious to Gram stain; visualization with light microscopy requires acid-fast stains such as the auramine-rhodamine or Ziehl-Neelsen stains.<xref ref-type="bibr" rid="article-156824.r6">[6]</xref><xref ref-type="bibr" rid="article-156824.r7">[7]</xref>&#x000a0;</p>
        <p>Mycobacteria are aerobic and slow-growing; several weeks of culture may be required to achieve a positive result.<xref ref-type="bibr" rid="article-156824.r8">[8]</xref>&#x000a0;The identification of&#x000a0;<italic toggle="yes">M tuberculosis&#x000a0;</italic>isolated from culture is typically based on morphologic and biochemical characteristics. Rapid diagnostic techniques such as nucleic acid amplification testing may be performed for the identification of&#x000a0;<italic toggle="yes">M tuberculosis&#x000a0;</italic>and can target gene sequences known to confer drug resistance.<xref ref-type="bibr" rid="article-156824.r7">[7]</xref></p>
      </sec>
      <sec id="article-156824.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Approximately one-third of the global population is infected with&#x000a0;<italic toggle="yes">M tuberculosis.&#x000a0;</italic>Despite being a treatable and curable condition, TB kills approximately 1.5 million people annually worldwide.<xref ref-type="bibr" rid="article-156824.r9">[9]</xref> However, the burden of infection disproportionately falls on low-income countries. High rates of infection, defined as greater than 300 per 100,000 population per year, are seen in India and countries in sub-Saharan Africa. Tuberculosis rates in Eastern Europe are as high as 154 per 100,000 population per year.<xref ref-type="bibr" rid="article-156824.r2">[2]</xref></p>
        <p>Countries with a low incidence of TB infection, such as the United States, are defined by an incidence of TB of less than 100 per 100,000 population per year.<xref ref-type="bibr" rid="article-156824.r9">[9]</xref>&#x000a0;A majority of cases in the United States occur in people who were born overseas.</p>
        <p>The incidence of TB is higher in males than females; in one study, the pulmonary TB rate in males was 31.8 cases per 100,000 person-years compared to 20.1 cases per 100,000 person-years in females.<xref ref-type="bibr" rid="article-156824.r10">[10]</xref>&#x000a0;Approximately 12% of newly diagnosed global TB occurs in people coinfected with HIV; the interpretation of interferon-gamma diagnostic results can be affected by the degree of HIV-induced immunosuppression.<xref ref-type="bibr" rid="article-156824.r11">[11]</xref><xref ref-type="bibr" rid="article-156824.r12">[12]</xref><xref ref-type="bibr" rid="article-156824.r13">[13]</xref>&#x000a0;</p>
        <p>Following inhalational exposure to the bacterium, approximately 5% to 15% of infected individuals will develop active TB during their lifetime. While latency may last for decades following infection, most patients who progress to active TB disease do so within the first 2 years&#x000a0;following exposure.<xref ref-type="bibr" rid="article-156824.r14">[14]</xref><xref ref-type="bibr" rid="article-156824.r15">[15]</xref></p>
      </sec>
      <sec id="article-156824.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Inhalation of the&#x000a0;<italic toggle="yes">M</italic>&#x000a0;<italic toggle="yes">tuberculosis</italic>&#x000a0;bacterium is&#x000a0;met by varying immune responses between hosts. The immune response in some patients, particularly those who are immunocompetent, is characterized by the elimination of the bacterium by alveolar macrophages. In other patients, the innate immune system in the lungs produces a granulomatous reaction to contain the bacterium called a tubercle.<xref ref-type="bibr" rid="article-156824.r16">[16]</xref></p>
        <p>A spectrum of containment from latent tuberculosis infection to active tuberculosis disease correlates with the bacteria escaping from the tubercle according to host-pathogen interactions.<xref ref-type="bibr" rid="article-156824.r17">[17]</xref><xref ref-type="bibr" rid="article-156824.r16">[16]</xref> A bacteremic phase may occur, particularly in those with HIV, and mycobacteria may hematogenously spread to any organ.<xref ref-type="bibr" rid="article-156824.r18">[18]</xref> The definition of latent TB infection is evidence of immunological response to&#x000a0;<italic toggle="yes">M tuberculosis</italic>&#x000a0;without evidence of clinical disease.<xref ref-type="bibr" rid="article-156824.r19">[19]</xref></p>
        <p>In the absence of treatment, the risk of reactivation of latent tuberculosis infection is 5% to 15% across the lifetime of the infected patient.<xref ref-type="bibr" rid="article-156824.r20">[20]</xref>&#x000a0;However, this risk varies depending on the coincident pathogen, host, and environmental factors.&#x000a0;Bacterial pathogenic factors include the varied virulence of different clades of&#x000a0;<italic toggle="yes">M tuberculosis</italic>&#x000a0;that co-evolve with human host populations and differences in progression to active disease between species within the&#x000a0;<italic toggle="yes">M tuberculosis</italic>&#x000a0;complex.<xref ref-type="bibr" rid="article-156824.r14">[14]</xref></p>
        <p>Host factors that increase the risk of progression to active TB disease include immunosuppression and advancing age. The age-related decline in the immune response, mutations in Toll-like receptors, T-cell depletion, and changes in the expression of cytokines such as interferon-gamma and tumor necrosis factor.<xref ref-type="bibr" rid="article-156824.r9">[9]</xref> Patients utilizing biological therapies for rheumatological diseases may also be at increased risk of reactivation from latent TB, as these treatments affect key cytokine responses in cellular immunity.<xref ref-type="bibr" rid="article-156824.r21">[21]</xref> Other conditions that decrease the immune response and are risk factors for progression to active TB include HIV infection, diabetes, smoking, malignancy, corticosteroid use, and solid organ or hematological transplant.<xref ref-type="bibr" rid="article-156824.r21">[21]</xref></p>
        <p>Bacterial factors include the varied virulence of different clades of <italic toggle="yes">M tuberculosis</italic> that co-evolve with human host populations and differences in progression to active disease between species within the <italic toggle="yes">M tuberculosis</italic> complex.<xref ref-type="bibr" rid="article-156824.r14">[14]</xref></p>
      </sec>
      <sec id="article-156824.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with latent TB infection are asymptomatic.<xref ref-type="bibr" rid="article-156824.r19">[19]</xref>&#x000a0;Therefore, obtaining a medical history is dual-purposed: identifying patients with indications for testing for latent TB infection and excluding active tuberculosis disease.</p>
        <p>Indications for latent TB infection testing include patients at high risk of reactivation in low-incidence countries, patients at high risk of a new TB infection, or patients at moderate-to-high risk of reactivation in a high-incidence area.<xref ref-type="bibr" rid="article-156824.r22">[22]</xref>&#x000a0;A thorough exploration of risk factors for reactivation is required; these risk factors include a personal history of hematological or solid organ transplantation, dialysis, silicosis, anti-tumor necrosis factor treatment, and HIV coinfection.<xref ref-type="bibr" rid="article-156824.r21">[21]</xref>&#x000a0;Additionally, individuals of all ages who are in contact with patients with active TB infection are at a significantly increased risk of developing a new TB infection.</p>
        <p>Symptoms that may indicate active TB disease include a cough for more than 2 weeks, shortness of breath, hemoptysis, chest pain, fevers, night sweats, and weight loss.<xref ref-type="bibr" rid="article-156824.r22">[22]</xref>&#x000a0;People at high risk for exposure to cases of pulmonary TB include prisoners, healthcare workers, homeless persons, illicit drug users, those with silicosis, and people who have emigrated from high TB incidence to low-incidence countries.<xref ref-type="bibr" rid="article-156824.r4">[4]</xref><xref ref-type="bibr" rid="article-156824.r23">[23]</xref><xref ref-type="bibr" rid="article-156824.r24">[24]</xref>&#x000a0;</p>
        <p>The physical examination should focus on identifying features of active TB disease, including pulmonary and extrapulmonary signs. Weight loss, sputum jars of hemoptysis, fevers, and diaphoresis may be indicative of active TB disease. Extrapulmonary signs include lymph node enlargement, skin changes such as erythema nodosum or panniculitis, pallor indicative of anemia, meningeal, peritoneal, and osteoarticular signs.<xref ref-type="bibr" rid="article-156824.r22">[22]</xref> Features that may predispose risk for reactivation seen on examination include intravascular catheters or arteriovenous fistulas for dialysis, signs of organ transplantation and treatment, and steroid-related changes.</p>
      </sec>
      <sec id="article-156824.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>No single test can accurately distinguish between active and latent TB disease.&#x000a0;The diagnosis of latent TB infection relies on evidence of cellular immune response to&#x000a0;<italic toggle="yes">M</italic>&#x000a0;<italic toggle="yes">tuberculosis&#x000a0;</italic>and the reasonable exclusion of active TB disease.</p>
        <p>
<bold>Immune-Based Testing</bold>
</p>
        <p>Immune-based tests include the tuberculin skin test (TST) and the interferon-gamma release assay (IGRA). TST and IGRA are frequently utilized in high-income, low-incidence countries where the Bacille Calmette&#x02013;Gu&#x000e9;rin (BCG) vaccine is less often used for population-based management of TB.<xref ref-type="bibr" rid="article-156824.r25">[25]</xref>&#x000a0;The TST and IGRA should lack the sensitivity and specificity to detect active TB and should not be used to diagnose active TB; mycobacterial culture and molecular methods are used for this purpose.<xref ref-type="bibr" rid="article-156824.r26">[26]</xref></p>
        <p>The TST involves intradermal administration of a small volume of tuberculin antigens (tuberculoprotein preparation, or PPD) to allow for T-cell&#x02013;mediated recognition and induration formation secondary to TB-sensitised T cells.<xref ref-type="bibr" rid="article-156824.r27">[27]</xref>&#x000a0;Developing skin test conversion following active <italic toggle="yes">M tuberculosis</italic> infection may take up to 12 weeks.<xref ref-type="bibr" rid="article-156824.r28">[28]</xref> Approximately&#x000a0;50% of&#x000a0;individuals with past exposure to <italic toggle="yes">M tuberculosis</italic> do not react when challenged with a TST; this may represent a failure of T<sub>H</sub>1-driven cellular immunity or that infection with the mycobacterium did not occur.<xref ref-type="bibr" rid="article-156824.r29">[29]</xref> If cellular immunity is intact and the patient has previously been exposed to the antigens, a delayed-type hypersensitivity reaction will result in induration and erythema.<xref ref-type="bibr" rid="article-156824.r30">[30]</xref> Patients return 2 to 5 days following PPD administration for measurement of skin induration by a skilled clinician.</p>
        <p>The TST is not specific for&#x000a0;<italic toggle="yes">M tuberculosis. </italic>Falsely positive results may occur in patients exposed to environmental NTM,&#x000a0;vaccinated with the BCG vaccine, or with past exposure to&#x000a0;<italic toggle="yes">M</italic>&#x000a0;<italic toggle="yes">tuberculosis</italic>&#x000a0;but have cleared the infection. Incorrect TST technique or interpretation may also contribute to a false-negative result. NTM that are cross-reactive with the TST include&#x000a0;<italic toggle="yes">Mycobacterium avium-intracellulare</italic><italic toggle="yes">,</italic>&#x000a0;<italic toggle="yes">Mycobacterium simiae</italic>, <italic toggle="yes">Mycobacterium scrofulaceum</italic>, and <italic toggle="yes">Mycobacterium kansasii. M kansasii</italic>&#x000a0;and&#x000a0;<italic toggle="yes">M avium-intracellulare</italic> complex can cause clinically significant pulmonary infections, particularly in patients with underlying structural lung disease.<xref ref-type="bibr" rid="article-156824.r31">[31]</xref><xref ref-type="bibr" rid="article-156824.r32">[32]</xref>&#x000a0;However, globally,&#x000a0;NTM&#x000a0;is a less important cause of false-positive TST results, except in areas of higher NTM but low <italic toggle="yes">M tuberculosis</italic> prevalence.<xref ref-type="bibr" rid="article-156824.r33">[33]</xref> False-negative results may occur in patients who have impaired cellular immunity.&#x000a0;<xref ref-type="bibr" rid="article-156824.r34">[34]</xref>&#x000a0;</p>
        <p>The IGRA is a blood test that measures&#x000a0;in vitro&#x000a0;cellular responses to&#x000a0;<italic toggle="yes">M</italic>&#x000a0;<italic toggle="yes">tuberculosis</italic>-specific&#x000a0;antigens not found in the BCG vaccine or most NTM.<xref ref-type="bibr" rid="article-156824.r34">[34]</xref><xref ref-type="bibr" rid="article-156824.r35">[35]</xref>&#x000a0;Three tubes of blood are required to perform an IGRA: a negative control, a positive control with phytohemagglutinin, and a tube specific for <italic toggle="yes">M tuberculosis</italic> antigens.<xref ref-type="bibr" rid="article-156824.r27">[27]</xref> The blood is incubated for up to 24 hours and separated into plasma; results are released as positive, negative, or indeterminate. Unlike the TST, IGRA tests will not react to prior BCG vaccinations or NTM.<xref ref-type="bibr" rid="article-156824.r36">[36]</xref></p>
        <p>IGRA has a higher specificity than TST for&#x000a0;<italic toggle="yes">M tuberculosis</italic>&#x000a0;exposure but is more expensive and resource-intensive in many countries.<xref ref-type="bibr" rid="article-156824.r37">[37]</xref>&#x000a0;However, emerging evidence in high-income countries shows that IGRAs can be cost-effective for detecting latent TB infection in high-risk populations.<xref ref-type="bibr" rid="article-156824.r37">[37]</xref><xref ref-type="bibr" rid="article-156824.r38">[38]</xref>&#x000a0;A false-negative IGRA can occur in patients with central nervous TB infection or an impaired immune response, including older patients&#x000a0;or those with an innate or acquired interferon-gamma deficiency.<xref ref-type="bibr" rid="article-156824.r39">[39]</xref><xref ref-type="bibr" rid="article-156824.r40">[40]</xref> False positive IGRA results may occur secondary to specimen contamination with live TB organisms.<xref ref-type="bibr" rid="article-156824.r41">[41]</xref>&#x000a0;An indeterminate result may be secondary to reduced immune responses to the mitogen control, as in immunosuppression, or secondary to elevated interferon-gamma in the negative controls, such as the presence of heterophile antibodies, incorrect antigens, or autoimmune conditions such as systemic lupus erythematosus and rheumatoid arthritis.<xref ref-type="bibr" rid="article-156824.r22">[22]</xref><xref ref-type="bibr" rid="article-156824.r42">[42]</xref></p>
        <p>There is limited utility&#x000a0;to using TST&#x000a0;or IGRA when monitoring the response to TB treatment. Though there may be a decline in IGRA-positive rates after TB treatment, many cases remain positive despite latent TB therapy.<xref ref-type="bibr" rid="article-156824.r43">[43]</xref><xref ref-type="bibr" rid="article-156824.r44">[44]</xref> Similarly, TST measures the hypersensitivity of T-cell responses to tuberculin rather than as a treatment response or immunity measure.<xref ref-type="bibr" rid="article-156824.r30">[30]</xref></p>
        <p>
<bold>Chest Radiography and Sputum Samples</bold>
</p>
        <p>A chest radiograph may be adequate to exclude active tuberculosis in patients without symptoms of TB disease. However, patients with clinical or radiological abnormalities should be further investigated for TB disease or other conditions. Other conditions that may mimic TB include silicosis, malignancy, sarcoidosis, autoimmune causes such as rheumatoid arthritis and vasculitis, and infections including NTM, <italic toggle="yes">Nocardia</italic>, <italic toggle="yes">Cryptococcus</italic>, <italic toggle="yes">Histoplasma,</italic> and <italic toggle="yes">Aspergillus.</italic><xref ref-type="bibr" rid="article-156824.r45">[45]</xref><xref ref-type="bibr" rid="article-156824.r46">[46]</xref><xref ref-type="bibr" rid="article-156824.r47">[47]</xref><xref ref-type="bibr" rid="article-156824.r48">[48]</xref><xref ref-type="bibr" rid="article-156824.r49">[49]</xref></p>
        <p>Another test for active TB is the evaluation of 3 early morning sputum samples for acid-fast staining, mycobacterial culture, and nucleic acid amplification testing.<xref ref-type="bibr" rid="article-156824.r22">[22]</xref>&#x000a0;Identifying&#x000a0;<italic toggle="yes">M tuberculosis</italic>&#x000a0;on a sputum sample is diagnostic for active&#x000a0;TB infection; such a patient can infect others and requires isolation. This situation also requires public health notification for contact tracing to limit community transmission of TB.<xref ref-type="bibr" rid="article-156824.r50">[50]</xref> Patients with isolated extrapulmonary manifestations of&#x000a0;TB are noninfectious.<xref ref-type="bibr" rid="article-156824.r51">[51]</xref></p>
      </sec>
      <sec id="article-156824.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Mycobacteria such as&#x000a0;<italic toggle="yes">M tuberculosis&#x000a0;</italic>are intrinsically resistant to most commonly used antibiotics.<xref ref-type="bibr" rid="article-156824.r52">[52]</xref>&#x000a0;The treatment regimen for latent TB infection typically comprises 1 or 2 drugs active against mycobacteria.<xref ref-type="bibr" rid="article-156824.r53">[53]</xref> In comparison, the standard treatment regimen for sensitive pulmonary TB disease is much more complex: rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, and if testing confirms susceptibility to rifampicin and isoniazid, continuation of those 2 drugs for an additional 4 months with cessation of the pyrazinamide and ethambutol.<xref ref-type="bibr" rid="article-156824.r53">[53]</xref><xref ref-type="bibr" rid="article-156824.r54">[54]</xref> Susceptibility testing cannot be used to guide treatment for latent TB as <italic toggle="yes">M tuberculosis</italic> cannot be cultured.<xref ref-type="bibr" rid="article-156824.r55">[55]</xref></p>
        <p>Individuals in close contact with patients with multidrug-resistant TB (MDR-TB) are more likely to have latent TB, and close contacts with active TB are more likely to have MDR-TB themselves.<xref ref-type="bibr" rid="article-156824.r56">[56]</xref><xref ref-type="bibr" rid="article-156824.r57">[57]</xref>&#x000a0;Despite this, the evidence to inform best practices regarding managing close contacts of MDR-TB is limited.<xref ref-type="bibr" rid="article-156824.r56">[56]</xref> Given the lack of evidence of better treatment outcomes in treating latent TB based on MDR-TB close contact susceptibilities, the selection of latent TB management in these cases has been guided by expert opinion and the discretion of the treating clinician on the individual risk of acquiring MDR-TB.<xref ref-type="bibr" rid="article-156824.r58">[58]</xref><xref ref-type="bibr" rid="article-156824.r59">[59]</xref></p>
        <p>The goal of latent TB infection treatment is to prevent progression to active disease. Given that most patients will not reactivate during their lifetime if untreated, the risk of this progression&#x000a0;must be balanced against the risk of toxicity from treatment,&#x000a0;particularly hepatotoxicity with isoniazid-based therapy.<xref ref-type="bibr" rid="article-156824.r60">[60]</xref><xref ref-type="bibr" rid="article-156824.r61">[61]</xref> To assist clinicians in evaluating this risk-benefit equation, several clinical calculators have been developed to estimate the likelihood that the patient has true-positive testing for latent TB, their risk of reactivation, and their risk of serious hepatotoxicity from the treatment of latent TB.<xref ref-type="bibr" rid="article-156824.r62">[62]</xref><xref ref-type="bibr" rid="article-156824.r63">[63]</xref></p>
        <p>The 3 most commonly utilized regimens for the treatment of latent tuberculosis are rifampicin monotherapy daily for 3 to 4 months, rifampicin or rifapentine plus isoniazid for 3 to 4 months, or isoniazid monotherapy daily for 6 to 9 months.<xref ref-type="bibr" rid="article-156824.r53">[53]</xref>&#x000a0;Choosing among these regimens is influenced by cost, efficacy, likelihood of adherence, and adverse effects, including hepatotoxicity.</p>
        <p>Isoniazid is an antimycobacterial antibiotic that inhibits the synthesis of the mycolic acids essential for the cell envelope of mycobacteria.<xref ref-type="bibr" rid="article-156824.r64">[64]</xref>&#x000a0;Isoniazid is cheaper than rifamycin but carries a higher risk of adverse effects. The rifamycins are a class of antibiotics that inhibit bacterial DNA-dependent RNA-polymerase and are active against a broad range of bacteria, including mycobacteria.<xref ref-type="bibr" rid="article-156824.r65">[65]</xref> The&#x000a0;rifamycins most useful for treating latent&#x000a0;TB are rifampicin and rifapentine; rifapentine has a longer half-life and can be&#x000a0;dosed&#x000a0;weekly.<xref ref-type="bibr" rid="article-156824.r66">[66]</xref></p>
        <p>The protective efficacy of established regimens for latent&#x000a0;TB ranges from 60% to 90% for up to 19 years.<xref ref-type="bibr" rid="article-156824.r67">[67]</xref>&#x000a0;In persons with HIV infection in areas with a high incidence of tuberculosis, the optimal duration of therapy for latent TB infection is not well established due to the risks of repeated or ongoing exposure and host immune status changes.<xref ref-type="bibr" rid="article-156824.r68">[68]</xref><xref ref-type="bibr" rid="article-156824.r69">[69]</xref></p>
      </sec>
      <sec id="article-156824.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Diagnosing latent TB infection can be challenging. No single test is adequate for diagnosis, and assessing for the condition requires careful clinical and radiological evaluation and interpretation of immunological tests. Patients with latent TB infection are asymptomatic by definition and detected solely through screening. The most pertinent differential diagnoses are&#x000a0;active&#x000a0;or previously treated&#x000a0;TB disease and other NTM infections&#x000a0;that predispose to falsely positive immune-based tests.<xref ref-type="bibr" rid="article-156824.r34">[34]</xref></p>
        <p>
<bold>Active Tuberculosis Disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The minimum requirement for the exclusion of active TB disease is the patient is asymptomatic of TB disease with a normal chest radiograph.<xref ref-type="bibr" rid="article-156824.r70">[70]</xref>&#x000a0;If there is uncertainty,&#x000a0;obtaining three early morning sputum samples for acid-fast staining, mycobacterial culture, and nucleic acid amplification testing must be considered. Signs or symptoms of extrapulmonary&#x000a0;TB disease may require imaging, biopsy, and lumbar puncture.</p>
          </list-item>
        </list>
        <p>
<bold>Resolved Tuberculosis Infection</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Asymptomatic patients with immunological evidence of prior exposure to&#x000a0;<italic toggle="yes">M tuberculosis&#x000a0;</italic>characterized by<italic toggle="yes">&#x000a0;</italic>a positive TST or IGRA may have had a previously treated or cleared&#x000a0;TB infection.&#x000a0;Obtaining a careful timeframe of prior exposures and treatment history is critical. The decision to treat latent TB infection is often a patient-specific risk-benefit analysis; clinical calculators may assist the clinician.<xref ref-type="bibr" rid="article-156824.r62">[62]</xref><xref ref-type="bibr" rid="article-156824.r63">[63]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Bacille&#x000a0;Calmette&#x02013;Gu&#x000e9;rin (BCG) Vaccination</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The TST is not specific for&#x000a0;<italic toggle="yes">M tuberculosis,</italic>&#x000a0;and false-positive results may occur in those vaccinated with BCG as derived from&#x000a0;<italic toggle="yes">M bovis.</italic><xref ref-type="bibr" rid="article-156824.r34">[34]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Nontuberculous Mycobacterial Infection</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The TST is not specific for&#x000a0;<italic toggle="yes">M tuberculosis,</italic>&#x000a0;and false-positive results may occur for those exposed to environmental NTM, such as&#x000a0;<italic toggle="yes">M avium-intracellulare&#x000a0;</italic>complex<italic toggle="yes">,</italic>&#x000a0;<italic toggle="yes">M simiae</italic>, <italic toggle="yes">M scrofulaceum</italic>, and <italic toggle="yes">M kansasii</italic>.<xref ref-type="bibr" rid="article-156824.r31">[31]</xref><xref ref-type="bibr" rid="article-156824.r32">[32]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-156824.s9" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>One of the most significant challenges in the treatment of latent TB infection is the difficulty in achieving an accurate diagnosis. The current diagnostic tests for <italic toggle="yes">M tuberculosis</italic> rely&#x000a0;on cellular immune responses to prior&#x000a0;exposure to antigens produced by the bacteria. These tests, particularly the TST, can be positive in patients who have cleared the infection and those with active pulmonary disease.<xref ref-type="bibr" rid="article-156824.r71">[71]</xref>&#x000a0;Next-generation diagnostics under development include immunodiagnostic biomarkers that seek to improve the capacity to differentiate latent TB infection.<xref ref-type="bibr" rid="article-156824.r32">[32]</xref></p>
      </sec>
      <sec id="article-156824.s10" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>The most concerning adverse effect of latent TB treatment is drug-induced hepatitis, which may require hospitalization for acute liver injury but is rarely&#x000a0;fatal.<xref ref-type="bibr" rid="article-156824.r72">[72]</xref><xref ref-type="bibr" rid="article-156824.r73">[73]</xref>&#x000a0;Drug-induced hepatotoxicity is most commonly seen with regimens containing isoniazid but can also occur with rifamycins.<xref ref-type="bibr" rid="article-156824.r74">[74]</xref> Risk factors for developing serious hepatotoxicity include higher pretreatment baseline transaminase levels, active liver disease, hypoalbuminemia, increased age, antiretroviral therapy, HIV infection, pretreatment hepatitis B surface antigen seropositivity, alcohol use disorder, coadministration of hepatotoxic medications, and pregnancy.<xref ref-type="bibr" rid="article-156824.r72">[72]</xref><xref ref-type="bibr" rid="article-156824.r73">[73]</xref><xref ref-type="bibr" rid="article-156824.r75">[75]</xref><xref ref-type="bibr" rid="article-156824.r76">[76]</xref><xref ref-type="bibr" rid="article-156824.r77">[77]</xref><xref ref-type="bibr" rid="article-156824.r78">[78]</xref><xref ref-type="bibr" rid="article-156824.r79">[79]</xref>&#x000a0;Hepatoxicity rates are higher for Indian patients compared to other populations; the etiology of this is unknown.<xref ref-type="bibr" rid="article-156824.r80">[80]</xref>&#x000a0;Children of all ethnicities have a higher incidence of hepatotoxicity compared to adults. Patients with risk factors for drug-induced hepatitis should have their liver function assessed before commencing antibiotic therapy and monthly until therapy is complete.<xref ref-type="bibr" rid="article-156824.r81">[81]</xref>&#x000a0;Patients should be educated about the symptoms associated with hepatitis and instructed to seek early evaluation should symptoms occur.&#x000a0;</p>
        <p>Peripheral neuropathy can be induced by isoniazid due to vitamin B6 deficiency.<xref ref-type="bibr" rid="article-156824.r82">[82]</xref>&#x000a0;Pyridoxine administration is not routinely recommended for all patients. Still, it should be prescribed to reduce the risk of neuropathy in patients with risk factors such as&#x000a0;pregnancy, HIV infection, diabetes, malnutrition, alcohol misuse, chronic kidney disease,&#x000a0;or advanced age.<xref ref-type="bibr" rid="article-156824.r83">[83]</xref><xref ref-type="bibr" rid="article-156824.r84">[84]</xref>&#x000a0;Rifamycin-related adverse effects include the orange-red discoloration of bodily fluids, hypersensitivity reactions, drug-drug interactions, renal impairment, hemolytic anemia, and thrombocytopenic purpura.<xref ref-type="bibr" rid="article-156824.r85">[85]</xref><xref ref-type="bibr" rid="article-156824.r86">[86]</xref><xref ref-type="bibr" rid="article-156824.r73">[73]</xref> Drug-drug interactions are common with rifamycins; a comprehensive medication history should be obtained before initiating rifamycin therapy. The anticoagulants warfarin, apixaban, and rivaroxaban present a relative contraindication to rifamycin therapy due to interactions in the cytochrome p450 enzyme pathway.<xref ref-type="bibr" rid="article-156824.r87">[87]</xref></p>
      </sec>
      <sec id="article-156824.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Treating latent TB infection kills the mycobacteria&#x000a0;before the development of active TB disease. The protective efficacy of established regimens for treating latent&#x000a0;TB infection ranges from 60% to 90%.<xref ref-type="bibr" rid="article-156824.r88">[88]</xref><xref ref-type="bibr" rid="article-156824.r89">[89]</xref>&#x000a0;Without treatment, 5 % to 15% of patients with latent TB infection will reactivate during their lifetime.<xref ref-type="bibr" rid="article-156824.r20">[20]</xref>&#x000a0;While there are known host, pathogen, and environmental factors that will put some individuals at higher risk,&#x000a0;it is impossible to perfectly predict which patients will go on to have TB disease.<xref ref-type="bibr" rid="article-156824.r9">[9]</xref><xref ref-type="bibr" rid="article-156824.r21">[21]</xref>&#x000a0;This equates to 90% of patients treated for&#x000a0;latent TB infection are exposed to the adverse effects of&#x000a0;treatment without benefit; careful assessment of patients is&#x000a0;required before commencing therapy for latent TB infection.</p>
      </sec>
      <sec id="article-156824.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Minimizing the risk of harm from the treatment of latent TB infection is imperative and is best accomplished through monitoring liver function in patients at increased risk of hepatotoxicity during regular clinic or case management visits.<xref ref-type="bibr" rid="article-156824.r81">[81]</xref>&#x000a0;The concerns regarding the risk of increasing drug resistance by treating latent TB infection have not been validated by comprehensive, systematic meta-analyses. <xref ref-type="bibr" rid="article-156824.r81">[81]</xref><xref ref-type="bibr" rid="article-156824.r90">[90]</xref> However, drug resistance surveillance systems should be in place to monitor for this potential outcome.<xref ref-type="bibr" rid="article-156824.r91">[91]</xref></p>
      </sec>
      <sec id="article-156824.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Medication adherence is one of the significant variables in successfully treating latent TB infection. There has been a&#x000a0;clinical shift to shorter and less complex treatment regimens to increase medication adherence.<xref ref-type="bibr" rid="article-156824.r92">[92]</xref>&#x000a0;Peer support, case management, and educational interventions also improve medication adherence.<xref ref-type="bibr" rid="article-156824.r93">[93]</xref>&#x000a0;Educating patients about the nature of TB infection and the importance of treatment promotes patient engagement and medication adherence. Patients must be counseled regarding the potential adverse effects of treatment, including the risk of hepatotoxicity and when to seek additional care.</p>
      </sec>
      <sec id="article-156824.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>In high-income, low-tuberculosis prevalence regions like the United States, where population-wide screening data for preventing active TB is lacking, public health interventions prioritize testing high-risk individuals and those prone to TB progression or new infections.<xref ref-type="bibr" rid="article-156824.r94">[94]</xref><xref ref-type="bibr" rid="article-156824.r95">[95]</xref>&#x000a0;TB-oriented clinics and public health services are pivotal in screening close contacts of active TB cases. Yet, services led by rheumatologists, primary care practitioners, sexual health services, and clinicians aid vulnerable populations in identifying high-risk patients and referring them for further assessment and treatment.<xref ref-type="bibr" rid="article-156824.r96">[96]</xref><xref ref-type="bibr" rid="article-156824.r97">[97]</xref><xref ref-type="bibr" rid="article-156824.r98">[98]</xref><xref ref-type="bibr" rid="article-156824.r99">[99]</xref></p>
        <p>Interprofessional collaboration involving pharmacists, nurses, and social workers significantly enhances patient safety and treatment outcomes. Pharmacists contribute expertise in treatment regimens for latent TB, managing risks like hepatotoxicity and drug interactions with rifamycin-containing therapies. TB-trained nurses or cultural health workers also aid in case management, optimizing medication adherence, and monitoring treatment-related adverse effects to ensure patient well-being. This integrated approach across healthcare disciplines is crucial in effectively managing latent TB in low-prevalence areas.</p>
        <p>Screening for and treating latent TB infection in high-income, low-incidence countries demands a coordinated and interprofessional approach involving physicians, advanced practice practitioners, nurses, pharmacists, and other health professionals. A comprehensive knowledge of and competence in TB screening methods, including interpreting TST and IGRA results, is required. Effective interprofessional communication, particularly surrounding social determinants and barriers to treatment, supports holistic patient care and improves outcomes. In high-income, low-incidence countries, the challenge lies in maintaining vigilance despite lower prevalence rates. Effective teamwork, continuous education, standardized protocols, and a patient-centered approach bolstered by ethical considerations are pivotal in achieving successful screening, treatment, and improved outcomes for patients with latent TB infection.</p>
      </sec>
      <sec id="article-156824.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=156824&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=156824">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/latent-tuberculosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=156824">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/156824/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=156824">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-156824.s16">
        <title>References</title>
        <ref id="article-156824.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nissapatorn</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kuppusamy</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Anuar</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Quek</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Latt</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Tuberculosis: clinical manifestations and outcomes.</article-title>
            <source>Southeast Asian J Trop Med Public Health</source>
            <year>2003</year>
            <volume>34 Suppl 2</volume>
            <fpage>147</fpage>
            <page-range>147-52</page-range>
            <pub-id pub-id-type="pmid">19238668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munteanu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cioran</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>van Hest</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abubakar</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Story</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chiotan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mahler</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Tuberculosis Surveillance in Romania Among Vulnerable Risk Groups Between 2015 and 2017.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2022</year>
            <volume>18</volume>
            <fpage>439</fpage>
            <page-range>439-446</page-range>
            <pub-id pub-id-type="pmid">35478731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jaramillo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weil</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Raviglione</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>L&#x000f6;nnroth</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review.</article-title>
            <source>Eur Respir J</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>1763</fpage>
            <page-range>1763-75</page-range>
            <pub-id pub-id-type="pmid">24525439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Getahun</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matteelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abubakar</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Aziz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Baddeley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barreira</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Den Boon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Borroto Gutierrez</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Bruchfeld</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Burhan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cavalcante</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cedillos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chaisson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chee</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Chesire</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Denholm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Falzon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gale-Rowe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gilpin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Girardi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Go</surname>
                <given-names>UY</given-names>
              </name>
              <name>
                <surname>Govindasamy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>D Grant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grzemska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Horsburgh</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Ismayilov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jaramillo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kranzer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lienhardt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>LoBue</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>L&#x000f6;nnroth</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Migliori</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Mosca</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mukadi</surname>
                <given-names>YD</given-names>
              </name>
              <name>
                <surname>Mwinga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nishikiori</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Oordt-Speets</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rangaka</surname>
                <given-names>MX</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rotz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sandgren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sa&#x000f1;&#x000e9; Schepisi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sch&#x000fc;nemann</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Sotgiu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stagg</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Sterling</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Tayeb</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uplekar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van der Werf</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vandevelde</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>van Kessel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van't Hoog</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Varma</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Vezhnina</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Voniatis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vonk Noordegraaf-Schouten</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weil</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weyer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Yoshiyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zellweger</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Raviglione</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.</article-title>
            <source>Eur Respir J</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>6</issue>
            <fpage>1563</fpage>
            <page-range>1563-76</page-range>
            <pub-id pub-id-type="pmid">26405286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pawe&#x00141;czyk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kremer</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The Molecular Genetics of Mycolic Acid Biosynthesis.</article-title>
            <source>Microbiol Spectr</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>MGM2</fpage>
            <page-range>MGM2-0003-2013</page-range>
            <pub-id pub-id-type="pmid">26104214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gizaw</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Abera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sisay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Desta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kreibich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gerwing-Adima</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gebre-Selassie</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The yield of Auramine O staining using led microscopy with bleach treated sputum samples for detection of pulmonary tuberculosis at St. Peter tuberculosis specialized hospital, Addis Ababa, Ethiopia.</article-title>
            <source>J Clin Tuberc Other Mycobact Dis</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>18</volume>
            <fpage>100140</fpage>
            <pub-id pub-id-type="pmid">31909226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Muni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Choubey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kumari</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>A Comparative Analysis of Microscopy, Culture, and the Xpert Mycobacterium tuberculosis/Rifampicin Assay in Diagnosing Pulmonary Tuberculosis in Human Immunodeficiency-Positive Individuals.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>15</volume>
            <issue>8</issue>
            <fpage>e42962</fpage>
            <pub-id pub-id-type="pmid">37667708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vongthilath-Moeung</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Poncet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Renzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schrenzel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Time to Detection of Growth for <italic>Mycobacterium tuberculosis</italic> in a Low Incidence Area.</article-title>
            <source>Front Cell Infect Microbiol</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>704169</fpage>
            <pub-id pub-id-type="pmid">34490143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Epidemiological features and temporal trends of HIV-negative tuberculosis burden from 1990 to 2019: a retrospective analysis based on the Global Burden of Disease Study 2019.</article-title>
            <source>BMJ Open</source>
            <year>2023</year>
            <month>Sep</month>
            <day>28</day>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>e074134</fpage>
            <pub-id pub-id-type="pmid">37770275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jim&#x000e9;nez-Corona</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Garc&#x000ed;a</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>DeRiemer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ferreyra-Reyes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bobadilla-del-Valle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cano-Arellano</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Canizales-Quintero</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Gamboa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Small</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Sifuentes-Osornio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ponce-de-Le&#x000f3;n</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Gender differentials of pulmonary tuberculosis transmission and reactivation in an endemic area.</article-title>
            <source>Thorax</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>61</volume>
            <issue>4</issue>
            <fpage>348</fpage>
            <page-range>348-53</page-range>
            <pub-id pub-id-type="pmid">16449260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of TB/HIV co-infection in countries except China: a systematic review and meta-analysis.</article-title>
            <source>PLoS One</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>e64915</fpage>
            <pub-id pub-id-type="pmid">23741419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trinh</surname>
                <given-names>QM</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Sintchenko</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Marais</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Tuberculosis and HIV co-infection-focus on the Asia-Pacific region.</article-title>
            <source>Int J Infect Dis</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>32</volume>
            <fpage>170</fpage>
            <page-range>170-8</page-range>
            <pub-id pub-id-type="pmid">25809776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aabye</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Ravn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>PrayGod</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jeremiah</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mugomela</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jepsen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Faurholt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Range</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Friis</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Changalucha</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>The impact of HIV infection and CD4 cell count on the performance of an interferon gamma release assay in patients with pulmonary tuberculosis.</article-title>
            <source>PLoS One</source>
            <year>2009</year>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>e4220</fpage>
            <pub-id pub-id-type="pmid">19156218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Understanding latent tuberculosis: a moving target.</article-title>
            <source>J Immunol</source>
            <year>2010</year>
            <month>Jul</month>
            <day>01</day>
            <volume>185</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-22</page-range>
            <pub-id pub-id-type="pmid">20562268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Behr</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Edelstein</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Ramakrishnan</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Revisiting the timetable of tuberculosis.</article-title>
            <source>BMJ</source>
            <year>2018</year>
            <month>Aug</month>
            <day>23</day>
            <volume>362</volume>
            <fpage>k2738</fpage>
            <pub-id pub-id-type="pmid">30139910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nazarova</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title><italic>Mycobacterium tuberculosis</italic>: Bacterial Fitness within the Host Macrophage.</article-title>
            <source>Microbiol Spectr</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30848232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ehrt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schnappinger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>KY</given-names>
              </name>
            </person-group>
            <article-title>Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis.</article-title>
            <source>Nat Rev Microbiol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>496</fpage>
            <page-range>496-507</page-range>
            <pub-id pub-id-type="pmid">29691481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pavlinac</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Lokken</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Walson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Crump</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>John-Stewart</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Mycobacterium tuberculosis bacteremia in adults and children: a systematic review and meta-analysis.</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>20</volume>
            <issue>7</issue>
            <fpage>895</fpage>
            <page-range>895-902</page-range>
            <pub-id pub-id-type="pmid">27287641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiazyk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>TB</given-names>
              </name>
            </person-group>
            <article-title>Latent tuberculosis infection: An overview.</article-title>
            <source>Can Commun Dis Rep</source>
            <year>2017</year>
            <month>Mar</month>
            <day>02</day>
            <volume>43</volume>
            <issue>3-4</issue>
            <fpage>62</fpage>
            <page-range>62-66</page-range>
            <pub-id pub-id-type="pmid">29770066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Comstock</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Livesay</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Woolpert</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>The prognosis of a positive tuberculin reaction in childhood and adolescence.</article-title>
            <source>Am J Epidemiol</source>
            <year>1974</year>
            <month>Feb</month>
            <volume>99</volume>
            <issue>2</issue>
            <fpage>131</fpage>
            <page-range>131-8</page-range>
            <pub-id pub-id-type="pmid">4810628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ai</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Ruan</surname>
                <given-names>QL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>QH</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Updates on the risk factors for latent tuberculosis reactivation and their managements.</article-title>
            <source>Emerg Microbes Infect</source>
            <year>2016</year>
            <month>Feb</month>
            <day>03</day>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>e10</fpage>
            <pub-id pub-id-type="pmid">26839146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loddenkemper</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lipman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zumla</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical Aspects of Adult Tuberculosis.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2015</year>
            <month>Feb</month>
            <day>06</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>a017848</fpage>
            <pub-id pub-id-type="pmid">25659379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Narasimhan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Macintyre</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Mathai</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for tuberculosis.</article-title>
            <source>Pulm Med</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>828939</fpage>
            <pub-id pub-id-type="pmid">23476764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iossifova</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kreiss</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Concurrent silicosis and pulmonary mycosis at death.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>318</fpage>
            <page-range>318-20</page-range>
            <pub-id pub-id-type="pmid">20113570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hermansen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lillebaek</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Ravn</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>QuantiFERON&#x02013;TB Gold In-Tube test performance in Denmark.</article-title>
            <source>Tuberculosis (Edinb)</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>94</volume>
            <issue>6</issue>
            <fpage>616</fpage>
            <page-range>616-21</page-range>
            <pub-id pub-id-type="pmid">25448289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Comstock</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research.</article-title>
            <source>Ann Intern Med</source>
            <year>2007</year>
            <month>Mar</month>
            <day>06</day>
            <volume>146</volume>
            <issue>5</issue>
            <fpage>340</fpage>
            <page-range>340-54</page-range>
            <pub-id pub-id-type="pmid">17339619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pollock</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Basu Roy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kampmann</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>How to use: interferon &#x003b3; release assays for tuberculosis.</article-title>
            <source>Arch Dis Child Educ Pract Ed</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>98</volume>
            <issue>3</issue>
            <fpage>99</fpage>
            <page-range>99-105</page-range>
            <pub-id pub-id-type="pmid">23580543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huebner</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Schein</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Bass</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>The tuberculin skin test.</article-title>
            <source>Clin Infect Dis</source>
            <year>1993</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>968</fpage>
            <page-range>968-75</page-range>
            <pub-id pub-id-type="pmid">8110954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morrison</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hopewell</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>359</fpage>
            <page-range>359-68</page-range>
            <pub-id pub-id-type="pmid">18450516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nayak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Acharjya</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Mantoux test and its interpretation.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-6</page-range>
            <pub-id pub-id-type="pmid">23130251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haimi-Cohen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zeharia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mimouni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Soukhman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Amir</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Skin indurations in response to tuberculin testing in patients with nontuberculous mycobacterial lymphadenitis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2001</year>
            <month>Nov</month>
            <day>15</day>
            <volume>33</volume>
            <issue>10</issue>
            <fpage>1786</fpage>
            <page-range>1786-8</page-range>
            <pub-id pub-id-type="pmid">11595991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindeboom</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kuijper</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Prins</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bruijnesteijn van Coppenraet</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Lindeboom</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Tuberculin skin testing is useful in the screening for nontuberculous mycobacterial cervicofacial lymphadenitis in children.</article-title>
            <source>Clin Infect Dis</source>
            <year>2006</year>
            <month>Dec</month>
            <day>15</day>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>1547</fpage>
            <page-range>1547-51</page-range>
            <pub-id pub-id-type="pmid">17109286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farhat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Greenaway</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>10</volume>
            <issue>11</issue>
            <fpage>1192</fpage>
            <page-range>1192-204</page-range>
            <pub-id pub-id-type="pmid">17131776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays.</article-title>
            <source>Microbiol Spectr</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">27763261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sha</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Performance of Interferon-Gamma Release Assays in the Diagnosis of Nontuberculous Mycobacterial Diseases-A Retrospective Survey From 2011 to 2019.</article-title>
            <source>Front Cell Infect Microbiol</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>571230</fpage>
            <pub-id pub-id-type="pmid">33680977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Augustynowicz-Kope&#x00107;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Siemion-Szcze&#x0015b;niak</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Zabost</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wyrostkiewicz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Filipczak</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Oniszh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gawryluk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Radzikowska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Korzybski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Szturmowicz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Interferon Gamma Release Assays in Patients with Respiratory Isolates of Non-Tuberculous Mycobacteria - a Preliminary Study.</article-title>
            <source>Pol J Microbiol</source>
            <year>2019</year>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-19</page-range>
            <pub-id pub-id-type="pmid">31050249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nienhaus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schablon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Diel</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of cost and cost-effectiveness of different TB-screening strategies.</article-title>
            <source>BMC Health Serv Res</source>
            <year>2011</year>
            <month>Sep</month>
            <day>30</day>
            <volume>11</volume>
            <fpage>247</fpage>
            <pub-id pub-id-type="pmid">21961888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Beale</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Arber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nikolayevskyy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Alagna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Manissero</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dowdy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Migliori</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Sotgiu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Duarte</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of cost-utility analyses of screening methods in latent tuberculosis infection in high-risk populations.</article-title>
            <source>BMC Pulm Med</source>
            <year>2022</year>
            <month>Oct</month>
            <day>05</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>375</fpage>
            <pub-id pub-id-type="pmid">36199061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Teeter</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Graves</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Graviss</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Characteristics Associated with Negative Interferon-&#x003b3; Release Assay Results in Culture-Confirmed Tuberculosis Patients, Texas, USA, 2013-2015.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>534</fpage>
            <page-range>534-540</page-range>
            <pub-id pub-id-type="pmid">29460756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamasue</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Komiya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Usagawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Umeki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nureki</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Ando</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hiramatsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nagai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kadota</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Factors associated with false negative interferon-&#x003b3; release assay results in patients with tuberculosis: A systematic review with meta-analysis.</article-title>
            <source>Sci Rep</source>
            <year>2020</year>
            <month>Jan</month>
            <day>31</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>1607</fpage>
            <pub-id pub-id-type="pmid">32005930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Slater</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parsonnet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Banaei</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Investigation of false-positive results given by the QuantiFERON-TB Gold In-Tube assay.</article-title>
            <source>J Clin Microbiol</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>50</volume>
            <issue>9</issue>
            <fpage>3105</fpage>
            <page-range>3105-7</page-range>
            <pub-id pub-id-type="pmid">22785197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powell</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Whitworth</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Bernardo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moonan</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Mazurek</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Unusual interferon gamma measurements with QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube tests.</article-title>
            <source>PLoS One</source>
            <year>2011</year>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>e20061</fpage>
            <pub-id pub-id-type="pmid">21687702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chee</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>KhinMar</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Barkham</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YT</given-names>
              </name>
            </person-group>
            <article-title>Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens.</article-title>
            <source>Eur Respir J</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>355</fpage>
            <page-range>355-61</page-range>
            <pub-id pub-id-type="pmid">19926734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dyrhol-Riise</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gran</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wentzel-Larsen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Blomberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Haanshuus</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>M&#x000f8;rkve</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country.</article-title>
            <source>BMC Infect Dis</source>
            <year>2010</year>
            <month>Mar</month>
            <day>08</day>
            <volume>10</volume>
            <fpage>57</fpage>
            <pub-id pub-id-type="pmid">20210999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McLean-Tooke</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary granulomas in a patient with positive ANCA and history of tuberculosis: case report.</article-title>
            <source>BMC Pulm Med</source>
            <year>2020</year>
            <month>Aug</month>
            <day>14</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>219</fpage>
            <pub-id pub-id-type="pmid">32795275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Jindal</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Sarcoidosis and tuberculosis: the same disease with different manifestations or similar manifestations of different disorders.</article-title>
            <source>Curr Opin Pulm Med</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>506</fpage>
            <page-range>506-16</page-range>
            <pub-id pub-id-type="pmid">22759770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Banner</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Tuberculosis. Clinical aspects and diagnosis.</article-title>
            <source>Arch Intern Med</source>
            <year>1979</year>
            <month>Dec</month>
            <volume>139</volume>
            <issue>12</issue>
            <fpage>1387</fpage>
            <page-range>1387-90</page-range>
            <pub-id pub-id-type="pmid">92919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saavedra</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Sierra</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Zuluaica</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Botero</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Diagnosing Caplan syndrome in a patient with silicosis and rheumatoid arthritis: imaging shows miliary pattern and cavity lung lesions.</article-title>
            <source>Lancet</source>
            <year>2023</year>
            <month>Jun</month>
            <day>24</day>
            <volume>401</volume>
            <issue>10394</issue>
            <fpage>2148</fpage>
            <pub-id pub-id-type="pmid">37355292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakatudde</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kasirye</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kiguli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Musoke</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>It is not always Tuberculosis! A case of pulmonary cryptococcosis in an immunocompetent child in Uganda.</article-title>
            <source>Afr Health Sci</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>990</fpage>
            <page-range>990-994</page-range>
            <pub-id pub-id-type="pmid">35222559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kasaie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Dowdy</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Timing of tuberculosis transmission and the impact of household contact tracing. An agent-based simulation model.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2014</year>
            <month>Apr</month>
            <day>01</day>
            <volume>189</volume>
            <issue>7</issue>
            <fpage>845</fpage>
            <page-range>845-52</page-range>
            <pub-id pub-id-type="pmid">24559425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaw</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mat Salleh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abdul Hamid</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thu</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of extrapulmonary tuberculosis in Brunei Darussalam: a retrospective cohort study.</article-title>
            <source>BMJ Open</source>
            <year>2023</year>
            <month>Aug</month>
            <day>23</day>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>e073266</fpage>
            <pub-id pub-id-type="pmid">37612110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gygli</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Borrell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Trauner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gagneux</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives.</article-title>
            <source>FEMS Microbiol Rev</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>354</fpage>
            <page-range>354-373</page-range>
            <pub-id pub-id-type="pmid">28369307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huaman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sterling</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Latent Tuberculosis Infection-An Update.</article-title>
            <source>Clin Chest Med</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>839</fpage>
            <page-range>839-848</page-range>
            <pub-id pub-id-type="pmid">31731988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nahid</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dorman</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Alipanah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cattamanchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chaisson</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Chaisson</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Grzemska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Higashi</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Hopewell</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Keshavjee</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Lienhardt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Merrifield</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Narita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peloquin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Raftery</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saukkonen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schaaf</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Sotgiu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Starke</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Migliori</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Vernon</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Oct</month>
            <day>01</day>
            <volume>63</volume>
            <issue>7</issue>
            <fpage>853</fpage>
            <page-range>853-67</page-range>
            <pub-id pub-id-type="pmid">27621353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heyckendorf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gillespie</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Ruhwald</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Culture-free proof of Mycobacterium tuberculosis - a new assay for viable bacteria.</article-title>
            <source>EBioMedicine</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>62</volume>
            <fpage>103117</fpage>
            <pub-id pub-id-type="pmid">33181467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Velen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Latent tuberculosis infection among contacts of patients with multidrug-resistant tuberculosis in New South Wales, Australia.</article-title>
            <source>ERJ Open Res</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">34549043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kritski</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rabahi</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Vieira</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Werneck-Barroso</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>Gde N</given-names>
              </name>
              <name>
                <surname>Bravo-de-Souza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Gontijo</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>LW</given-names>
              </name>
            </person-group>
            <article-title>Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>153</volume>
            <issue>1</issue>
            <fpage>331</fpage>
            <page-range>331-5</page-range>
            <pub-id pub-id-type="pmid">8542139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Werf</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sandgren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manissero</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Management of contacts of multidrug-resistant tuberculosis patients in the European Union and European Economic Area.</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2012</year>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>426</fpage>
            <pub-id pub-id-type="pmid">22640458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fox</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Schaaf</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Mandalakas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chiappini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zumla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marais</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>147</fpage>
            <page-range>147-153</page-range>
            <pub-id pub-id-type="pmid">27592087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nolan</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Buskin</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.</article-title>
            <source>JAMA</source>
            <year>1999</year>
            <month>Mar</month>
            <day>17</day>
            <volume>281</volume>
            <issue>11</issue>
            <fpage>1014</fpage>
            <page-range>1014-8</page-range>
            <pub-id pub-id-type="pmid">10086436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ngongondo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miyahara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Bisson</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumwenda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lavenberg</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Nyirenda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kidonge</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Hosseinipour</surname>
                <given-names>MC</given-names>
              </name>
              <collab>AIDS Clinical Trials Group A5274 (REMEMBER) Study Team</collab>
            </person-group>
            <article-title>Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>78</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-61</page-range>
            <pub-id pub-id-type="pmid">29406428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puyat</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Shulha</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Balshaw</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>How Well Does TSTin3D Predict Risk of Active Tuberculosis in the Canadian Immigrant Population? An External Validation Study.</article-title>
            <source>Clin Infect Dis</source>
            <year>2021</year>
            <month>Nov</month>
            <day>02</day>
            <volume>73</volume>
            <issue>9</issue>
            <fpage>e3486</fpage>
            <page-range>e3486-e3495</page-range>
            <pub-id pub-id-type="pmid">32556316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scolarici</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dekitani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sokol-Anderson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoft</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A scoring strategy for progression risk and rates of treatment completion in subjects with latent tuberculosis.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>e0207582</fpage>
            <pub-id pub-id-type="pmid">30440033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Timmins</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Deretic</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of action of isoniazid.</article-title>
            <source>Mol Microbiol</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>62</volume>
            <issue>5</issue>
            <fpage>1220</fpage>
            <page-range>1220-7</page-range>
            <pub-id pub-id-type="pmid">17074073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wehrli</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Rifampin: mechanisms of action and resistance.</article-title>
            <source>Rev Infect Dis</source>
            <year>1983</year>
            <season>Jul-Aug</season>
            <volume>5 Suppl 3</volume>
            <fpage>S407</fpage>
            <page-range>S407-11</page-range>
            <pub-id pub-id-type="pmid">6356275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zheng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough?</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2017</year>
            <volume>11</volume>
            <fpage>2957</fpage>
            <page-range>2957-2968</page-range>
            <pub-id pub-id-type="pmid">29066867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lobue</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Treatment of latent tuberculosis infection: An update.</article-title>
            <source>Respirology</source>
            <year>2010</year>
            <month>May</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>603</fpage>
            <page-range>603-22</page-range>
            <pub-id pub-id-type="pmid">20409026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zenner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Beer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lipman</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Stagg</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>van der Werf</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis.</article-title>
            <source>Ann Intern Med</source>
            <year>2017</year>
            <month>Aug</month>
            <day>15</day>
            <volume>167</volume>
            <issue>4</issue>
            <fpage>248</fpage>
            <page-range>248-255</page-range>
            <pub-id pub-id-type="pmid">28761946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Person</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Sterling</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Treatment of latent tuberculosis infection in HIV: shorter or longer?</article-title>
            <source>Curr HIV/AIDS Rep</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>259</fpage>
            <page-range>259-66</page-range>
            <pub-id pub-id-type="pmid">22581360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sia</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Wieland</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Current concepts in the management of tuberculosis.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>86</volume>
            <issue>4</issue>
            <fpage>348</fpage>
            <page-range>348-61</page-range>
            <pub-id pub-id-type="pmid">21454737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zellweger</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Sotgiu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corradi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Durando</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis of latent tuberculosis infection (LTBI): currently available tests, future developments, and perspectives to eliminate tuberculosis (TB).</article-title>
            <source>Med Lav</source>
            <year>2020</year>
            <month>Jun</month>
            <day>26</day>
            <volume>111</volume>
            <issue>3</issue>
            <fpage>170</fpage>
            <page-range>170-183</page-range>
            <pub-id pub-id-type="pmid">32624559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aouam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chaabane</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Loussa&#x000ef;ef</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ben Romdhane</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Boughattas</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Chakroun</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Adverse effects of antitubercular drugs: epidemiology, mechanisms, and patient management].</article-title>
            <source>Med Mal Infect</source>
            <year>2007</year>
            <month>May</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>253</fpage>
            <page-range>253-61</page-range>
            <pub-id pub-id-type="pmid">17336011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Trajman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Adjobimey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruslami</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eisenbeis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fregonese</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Valiquette</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Benedetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>318</fpage>
            <page-range>318-329</page-range>
            <pub-id pub-id-type="pmid">31866327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fountain</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Tolley</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Self</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Rifampin hepatotoxicity associated with treatment of latent tuberculosis infection.</article-title>
            <source>Am J Med Sci</source>
            <year>2009</year>
            <month>May</month>
            <volume>337</volume>
            <issue>5</issue>
            <fpage>317</fpage>
            <page-range>317-20</page-range>
            <pub-id pub-id-type="pmid">19295414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schaberg</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rebhan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lode</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.</article-title>
            <source>Eur Respir J</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>10</issue>
            <fpage>2026</fpage>
            <page-range>2026-30</page-range>
            <pub-id pub-id-type="pmid">8902462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franks</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Binkin</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Snider</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Rokaw</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Isoniazid hepatitis among pregnant and postpartum Hispanic patients.</article-title>
            <source>Public Health Rep</source>
            <year>1989</year>
            <season>Mar-Apr</season>
            <volume>104</volume>
            <issue>2</issue>
            <fpage>151</fpage>
            <page-range>151-5</page-range>
            <pub-id pub-id-type="pmid">2495549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yimer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Amogne</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Makonnen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Habtewold</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petros</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Aderaye</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schuppe-Koistinen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lindquist</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aklillu</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>e94271</fpage>
            <pub-id pub-id-type="pmid">24714066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Balamurugan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saha</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Pandey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Mehra</surname>
                <given-names>NK</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2002</year>
            <month>Oct</month>
            <day>01</day>
            <volume>166</volume>
            <issue>7</issue>
            <fpage>916</fpage>
            <page-range>916-9</page-range>
            <pub-id pub-id-type="pmid">12359646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anand</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Seth</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Puri</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment.</article-title>
            <source>Med J Armed Forces India</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>62</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-9</page-range>
            <pub-id pub-id-type="pmid">27407844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steele</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Burk</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>DesPrez</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Toxic hepatitis with isoniazid and rifampin. A meta-analysis.</article-title>
            <source>Chest</source>
            <year>1991</year>
            <month>Feb</month>
            <volume>99</volume>
            <issue>2</issue>
            <fpage>465</fpage>
            <page-range>465-71</page-range>
            <pub-id pub-id-type="pmid">1824929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study.</article-title>
            <source>Med Sci Monit</source>
            <year>2020</year>
            <month>Mar</month>
            <day>07</day>
            <volume>26</volume>
            <fpage>e920350</fpage>
            <pub-id pub-id-type="pmid">32145061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aita</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Calame</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Peripheral neuropathy secondary to isoniazid-induced pyridoxine deficiency.</article-title>
            <source>Md State Med J</source>
            <year>1972</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>10</issue>
            <fpage>68</fpage>
            <page-range>68-70</page-range>
            <pub-id pub-id-type="pmid">4353461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snider</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Pyridoxine supplementation during isoniazid therapy.</article-title>
            <source>Tubercle</source>
            <year>1980</year>
            <month>Dec</month>
            <volume>61</volume>
            <issue>4</issue>
            <fpage>191</fpage>
            <page-range>191-6</page-range>
            <pub-id pub-id-type="pmid">6269259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ZILBER</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>BAJDAKOVA</surname>
                <given-names>ZL</given-names>
              </name>
              <name>
                <surname>GARDASJAN</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>KONOVALOV</surname>
                <given-names>NV</given-names>
              </name>
              <name>
                <surname>BUNINA</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>BARABADZE</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>THE PREVENTION AND TREATMENT OF ISONIAZID TOXICITY IN THE THERAPY OF PULMONARY TUBERCULOSIS. 2. AN ASSESSMENT OF THE PROPHYLACTIC EFFECT OF PYRIDOXINE IN LOW DOSAGE.</article-title>
            <source>Bull World Health Organ</source>
            <year>1963</year>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>457</fpage>
            <page-range>457-81</page-range>
            <pub-id pub-id-type="pmid">14099673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Collazos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mayo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>1999</year>
            <month>Nov</month>
            <volume>78</volume>
            <issue>6</issue>
            <fpage>361</fpage>
            <page-range>361-9</page-range>
            <pub-id pub-id-type="pmid">10575418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Girling</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Hitze</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Adverse reactions to rifampicin.</article-title>
            <source>Bull World Health Organ</source>
            <year>1979</year>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-9</page-range>
            <pub-id pub-id-type="pmid">311712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacDougall</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Canonica</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Keh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>P Phan</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Louie</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management.</article-title>
            <source>Pharmacotherapy</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>343</fpage>
            <page-range>343-361</page-range>
            <pub-id pub-id-type="pmid">35152432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy.</article-title>
            <source>Tuberc Respir Dis (Seoul)</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-12</page-range>
            <pub-id pub-id-type="pmid">29332319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Comstock</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>3</volume>
            <issue>10</issue>
            <fpage>847</fpage>
            <page-range>847-50</page-range>
            <pub-id pub-id-type="pmid">10524579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>den Boon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matteelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Getahun</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis.</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>8</issue>
            <fpage>1065</fpage>
            <page-range>1065-71</page-range>
            <pub-id pub-id-type="pmid">27393541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balcells</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Godfrey-Faussett</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Isoniazid preventive therapy and risk for resistant tuberculosis.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2006</year>
            <month>May</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>744</fpage>
            <page-range>744-51</page-range>
            <pub-id pub-id-type="pmid">16704830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sterling</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Njie</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zenner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Reves</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Horsburgh</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Crane</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Burgos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>LoBue</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Winston</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Belknap</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2020</year>
            <month>Feb</month>
            <day>14</day>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">32053584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirsch-Moverman</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Colson</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Bethel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Franks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>El-Sadr</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Can a peer-based intervention impact adherence to the treatment of latent tuberculous infection?</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>1178</fpage>
            <page-range>1178-85</page-range>
            <pub-id pub-id-type="pmid">23928167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahwati</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Feltner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Halpern</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Woodell</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Boland</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Amick</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Jonas</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Sep</month>
            <day>06</day>
            <volume>316</volume>
            <issue>9</issue>
            <fpage>970</fpage>
            <page-range>970-83</page-range>
            <pub-id pub-id-type="pmid">27599332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>US Preventive Services Task Force</collab>
              <name>
                <surname>Mangione</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Cabana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chelmow</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Coker</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Donahue</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Ja&#x000e9;n</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ogedegbe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Stevermer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Underwood</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement.</article-title>
            <source>JAMA</source>
            <year>2023</year>
            <month>May</month>
            <day>02</day>
            <volume>329</volume>
            <issue>17</issue>
            <fpage>1487</fpage>
            <page-range>1487-1494</page-range>
            <pub-id pub-id-type="pmid">37129649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kunin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Timlin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lemoh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sheffield</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hazara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Improving screening and management of latent tuberculosis infection: development and evaluation of latent tuberculosis infection primary care model.</article-title>
            <source>BMC Infect Dis</source>
            <year>2022</year>
            <month>Jan</month>
            <day>12</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <pub-id pub-id-type="pmid">35022023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerani</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Strick</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>A Pilot TB Screening Model in a U.S. Prison Population Using Tuberculin Skin Test and Interferon Gamma Release Assay Based on Country of Origin.</article-title>
            <source>J Correct Health Care</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>259</fpage>
            <page-range>259-264</page-range>
            <pub-id pub-id-type="pmid">34652245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rendleman</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Mandated tuberculosis screening in a community of homeless people.</article-title>
            <source>Am J Prev Med</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>108</fpage>
            <page-range>108-13</page-range>
            <pub-id pub-id-type="pmid">10490052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156824.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehta</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zapantis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Petryna</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Efthimiou</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Screening Optimization of Latent Tuberculosis Infection in Rheumatoid Arthritis Patients.</article-title>
            <source>Arthritis</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>569620</fpage>
            <pub-id pub-id-type="pmid">26294972</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
